RuxolitinibLack of efficacy following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2039卷 / 1期

关键词：

D O I：

10.1007/s40278-024-72939-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：502 / 502

相关论文

共 50 条

[21] IbrutinibLack of efficacy following off-label use: case report
Reactions Weekly, 2025, 2042 (1) : 209 - 209
[22] InterferonLack of efficacy following off-label use: case report
Reactions Weekly, 2024, 2025 (1) : 231 - 231
[23] VedolizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1938 (1) : 1250 - 1250
[24] TocilizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1887 (1) : 643 - 643
[25] DexamethasoneLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1936 (1) : 195 - 195
[26] ApixabanLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 89 - 89
[27] CabazitaxelLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1980 (1) : 102 - 102
[28] OxcarbazepineLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1905 (1) : 409 - 409
[29] Catequentinib/sintilimabLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1958 (1) : 135 - 135
[30] Dexamethasone/tocilizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1968 (1) : 122 - 122

← 1 2 3 4 5 →